Table 3. Meta-analysis of reduced E-cadherin expression and clinicopathological features in breast cancer.
| No. of studies | Pheterogeneity | I2(%) | Effect Model | Pooled OR(95%CI) | P Value | |
|---|---|---|---|---|---|---|
| Tumor size(≥ 2 vs.< 2) | 12 | 0.734 | 0.0 | Fixed model | 1.38 (1.18,1.60) | < 0.001 |
| Age(≥ 50 vs.< 50) | 12 | 0.205 | 25.0 | Fixed model | 1.03 (0.85,1.24) | 0.706 |
| Histological grade(II/IIIvs.I) | 14 | 0.001 | 63.6 | Random model | 1.44 (1.06,1.96) | 0.02 |
| TNM stage(T3/T4vs.T1/T2) | 7 | 0.086 | 45.9 | Fixed model | 2.44 (1.75,3.41) | < 0.001 |
| Pathological type(IDC vs.Others) | 7 | 0.629 | 0.0 | Fixed model | 0.77 (0.59,1.00) | 0.054 |
| Menopause status(Post vs.Pre) | 6 | 0.341 | 11.6 | Fixed model | 1.20 (0.90,1.60) | 0.219 |
| Lymph node status(+ vs.−) | 15 | < 0.001 | 72.1 | Random model | 1.55 (1.15,2.10) | 0.005 |
| ER status(− vs.+) | 12 | 0.002 | 61.8 | Random model | 1.32 (0.94,1.84) | 0.108 |
| PR status(− vs.+) | 8 | 0.399 | 4.0 | Fixed model | 1.44 (1.10,1.88) | 0.007 |
| Her2 status(≥ 2+ vs.1+) | 5 | 0.197 | 33.6 | Fixed model | 1.36 (0.86,2.16) | 0.185 |